PYX Resources: Achieving volume and diversification milestones. Watch the video here.
“Post SPRINTER we were lead to believe that many interested parties
were in discusssion with SNG and there was a very real prospect of dosing patients”
And that’s exactly why we do not want a pointless hand holding update saying “We’re on track”
Because until we have signed contracts and agreed dates with trial hospitals, delivered drugs and have regulatory agreements a date it’s not guaranteed.
As WPA pointed out we are 25 days into a 6 month window. Anything could happen in that time to disrupt Synairgen’s plan and an update now would be as useful as the winter trials update at the AGM.
When the company know the patients will be dosed on x date they will tell us.
If the company for any reason isn’t going to achieve H1 then they will update the market.
The company have responded to emails and nothing in those emails said Delay
Now that is the most sensible post today WPA
Oh and Doc you took great pleasure in telling everyone you’d blocked me only to keep following my posts like a lost puppy and commenting on them just as you’ve done tonight.
Leave me alone and go back to your owner
Not the magic unavoidable trial failure if they’d only known what Doc D knew.
Sadly when reviewing your posts Doc D your level of trial knowledge is somewhat under par.
It seems TFG don’t agree with your view on our CEO. I’m guessing they realise that trials fail and epidemics have a changing landscape.
When they decide to ditch the CEO I might admit you’re right but I won’t hold my breath.
There’s a great deal is shareholder activism TFG could bring to bear if they so wished.
Silence from them speaks to the foundation behind my remarks.
What’s your foundation for believing the board and TFG are wrong?
We have this large investor who doesn’t lack the expertise to realise what is so obvious to you and Spacman and a number of others on this board and yet they’ve not changed anything or told the board not to hire these people.
Why is that?
CMO
Risk Management and Patient Safety: Biotech companies operate in a highly regulated environment where patient safety and risk management are paramount. The CMO plays a critical role in ensuring that clinical trials are conducted ethically and adhere to the highest standards of patient safety
Perhaps as we’re designing trials both now and at P3 we need the role?
If I’m following this thread properly.
The CEO is useless as is the CMO and CFO. The two non executive directors Flic and Amanda are no better.
The last update on Winter trials didn’t prove to be accurate.
But we’d like an update from these apparently “useless people” telling us we are on track because that will calm the nerves!
If I missed the logic in that argument feel free to explain?
Oh dear
Character assassination by innuendo. This poster doesn’t like the CEO or CMO or CFO and now adds two other targets to his long list.
But who is this poster who needs his hand holding with pointless updates saying “we’re on track”. He’s the one telling us the company was going to enter a 2bn SPAC deal.
When the company have a trial start date they will tell us. If there’s a delay they will update the market. Until then we wait for the substantial update we need not this nonsense from his latest moanalogue.
Our largest shareholder hasn’t replaced any of the board or changed the plan or timeframe. I find their actions far more believable than his posts.
Of course you do Aether. Goodbye
Aether
Posted in: SNG
Posts: 2,400
Price: 6.08
No Opinion
RE: Canary in the Goldmine15 Jan 2024 12:28
Fruits do you live with Tommy in a flat share like Bert and Ernie?
The drug works but to be useful commercially we have to prove we know in which patients it makes sense to administer it. Thats the missing part to this puzzle that the next trials will hopefully solve.
We are back at p2 because we need to perform a pilot trial as proof of concept to a BP that we can identify the correct patient group where our drug works well.
We could have done that at a P3 if we had the funds but we don’t so we need to convince BP we have a product worth investing in to get us to a P3.
Some people say that’s a failure of the board but that’s nonsense.
We have a few hindsight chat board pseudo scientists who don’t even understand the trials we ran let alone how to design a successful one.
Mentions inhaled interferon and our drug
https://www.sciencedirect.com/science/article/abs/pii/S1044532324000010
I’m guessing they don’t see a few hundred thousand shares need to be bought by directors to show faith in the company. TFG have shown faith in both the directors and the company in millions!!
Perhaps Professional should put a 2m order in tomorrow?
Directors ousted = zero
Https://ajsuccr.org/uploads/IMG_231275.pdf
Some themes mirror Synairgens approach
Asthma increases if Individuals have multiple allergens [52]. Rhi- novirus infection is the main reason of acute disease. If an individ- ual is genetically at risk of asthma, initial whistling due to rhino- virus also increase the risk of asthma, when individual becomes 6 years old[53].IFN is an interferon that inhibit viral replications. Infected epithelial cells accept to damage through infection, the cells produced large amount of Th2 (TSLP) which trigger dendrit- ic cells and enhanced allergies, however exogenous IFN-b utilize antiviral characteristics.
Conclusion
The pathology of asthma generally contains the collaboration of lymphocytes and EP cells. Subsequently, the most capable medi- cations to cure allergic asthma is now licensed or under progress to overcome the type 2 immunity. Mostly patients do not require biological therapies, if they use their general medicines daily or in a week. Yet, the most appropriate biological treatment for acute severe asthma with lapping phenotypes is quite blurred, hence needing more deleterious and prophesy biomarkers which tolerate a well patient selection.